Enquirer Consulting Group

Reachable Buyer Map

Prepared for Jenna Chrystal · Amici Procurement Solutions · August 2026
Lab operations software is bought by a handful of roles that sit in very different places depending on how old the company is. This map is the reachable version of that market in the United Kingdom, with the US layer alongside it: the segments where the problem is expensive enough to fund a platform, who signs inside each one, and roughly how many sit there. It describes the market rather than your business, and there is nothing to buy at the end of it.
UK biotech and therapeutics companies
The core of the map. Most are small enough that nobody owns purchasing as a full job, which is precisely why the problem is felt daily and solved badly.
Who signs: lab operations manager, head of procurement, finance director, chief operating officer, and at the smallest firms the founder.
1,200 to 1,700
UK biopharmaceutical and therapeutics companies, of which a minority run wet lab space at any real scale
Contract research and manufacturing sites
Higher spend, tighter compliance and a purchasing function that already exists, so the sale is a process argument rather than a first system. Longer cycle, larger seat count.
Who signs: head of procurement, supply chain manager, quality lead, lab operations director, finance controller.
400 to 700
contract research, testing and development and manufacturing sites in the United Kingdom serving life science clients
University and institute research labs
Public purchasing rules, framework agreements and a core facilities layer that buys like a business. Slower to enter and very hard to displace once inside, which cuts both ways.
Who signs: head of research operations, core facility manager, procurement officer, laboratory manager, principal investigator on larger grants.
60 to 90
UK universities running substantial wet lab research, out of roughly 130 to 150 institutions in total; each holds many separately budgeted labs
Science parks, incubators and shared labs
Not a buyer so much as a door. One relationship with the operator puts the platform in front of a cohort of tenant companies at the exact moment each of them starts to buy.
Who signs: park or facility director, lab operations manager, tenant services lead, head of business development.
100 to 150
science parks, bioincubators and shared laboratory operators in the United Kingdom, each housing tens of tenant companies
The United States life science layer
The same buyer with a different vocabulary and a much larger population, clustered in a handful of metro areas. Reaching it is a targeting exercise rather than a market entry one.
Who signs: lab operations manager, director of procurement, controller, facilities and EHS lead, chief operating officer.
3,000 to 4,500
US biotechnology and life science companies operating their own laboratory space, concentrated in Boston, the Bay Area, San Diego, the Research Triangle and the Maryland corridor
The newly funded
The single best moment to arrive, and the one segment that cannot be held as a static list. A company that raises a round staffs a lab within months, and the purchasing problem is created in that window.
Who signs: founder or chief executive, chief scientific officer, first operations hire, fractional finance lead.
A moving list, not a fixed one
no register marks the point where a company starts buying at volume, so this layer is built from funding and hiring events rather than from a directory

Where the openings are

1
The buying trigger is a funding round, not a quarter. Procurement pain is created the month a company staffs a lab and starts placing dozens of small orders with different suppliers. That moment is visible from funding announcements and first operations hires, which makes the highest intent audience in this market a moving list rather than a directory. A channel refreshed against events catches it. A purchased list never does.
2
Three people feel it, and only one of them signs. The scientist feels the delay, finance feels the ledger, and whoever owns compliance feels the audit trail. A single message reaches one of the three and reads as noise to the other two. Named audiences with separate first lines is the difference between a reply and a delete.
3
Incubators concentrate a cohort you would otherwise chase one by one. A shared lab operator sits in front of tens of tenant companies, each about to hit the same problem at a slightly different time. That is one relationship instead of a hundred approaches, and it is a partnership conversation rather than a sales one.
4
Regulated inventory is a second sale to the same logo, years later. A company that buys for research buys again, differently, when it runs its first regulated batch and a quality lead enters the room. That is a different seat, a different trigger and a different message, and it usually arrives without anyone watching for it.
Built from public market data, counts banded deliberately. These are company and site counts rather than opportunity counts, and sector definitions are self-reported, so the boundary between a life science company and a service supplier is softer than the bands suggest.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com